252 related articles for article (PubMed ID: 35853671)
1. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
Groeneveldt C; Kinderman P; van Stigt Thans JJC; Labrie C; Griffioen L; Sluijter M; van den Wollenberg DJM; Hoeben RC; den Haan JMM; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35853671
[TBL] [Abstract][Full Text] [Related]
2. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
4. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
[TBL] [Abstract][Full Text] [Related]
5. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
[TBL] [Abstract][Full Text] [Related]
7. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
8. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
10. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
[TBL] [Abstract][Full Text] [Related]
11. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
12. An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance cancer chemotherapy and immunotherapy.
Wang S; Li Y; Xu C; Dong J; Wei J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458640
[TBL] [Abstract][Full Text] [Related]
13. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C; Kinderman P; Griffioen L; Rensing O; Labrie C; van den Wollenberg DJM; Hoeben RC; Coffey M; Loghmani H; Verdegaal EME; Welters MJP; van der Burg SH; van Hall T; van Montfoort N
Cancer Immunol Res; 2024 Mar; 12(3):334-349. PubMed ID: 38194598
[TBL] [Abstract][Full Text] [Related]
15. Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Groeneveldt C; van Ginkel JQ; Kinderman P; Sluijter M; Griffioen L; Labrie C; van den Wollenberg DJM; Hoeben RC; van der Burg SH; Ten Dijke P; Hawinkels LJAC; van Hall T; van Montfoort N
Cancer Res Commun; 2023 Feb; 3(2):325-337. PubMed ID: 36860656
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
[TBL] [Abstract][Full Text] [Related]
17. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
18. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
